Research programme: Gram-negative infection therapeutics - Aurobac Therapeutics
Alternative Names: ATX3Latest Information Update: 27 Sep 2024
At a glance
- Originator Aurobac Therapeutics
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Gram-negative infections